1. Siegel RL, Miller KD, Jemal A (2019): Cancer statistics, 2019. CA Cancer J Clin 69: 7-34.
2.
Kim ST, Jeong H, Woo OH, et al. (2013): Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 36: 224-231.
3.
Ogiya R, Niikura N, Kumaki N, et al. (2016): Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci 107: 1730-1735.
4.
Zheng S, Bai J, Li J, et al. (2012): The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years. Int J Cancer 131: 2622-2631.
5.
Adams S, Schmid P, Rugo HS, et al. (2019): Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30: 397-404.
6.
Emens LA, Cruz C, Eder JP, et al. (2019): Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol 5: 74-82.
7.
Planes-Laine G, Rochigneux P, Bertucci F, et al. (2019): PD-1/PD-L1 targeting in breast cancer: The first clinical evidences are emerging. A literature review. Cancers (Basel) 11: 1033.
8.
Angelico G, Broggi G, Tinnirello G, et al. (2023): Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: A review of current evidence and prognostic implications from pathologist’s perspective. Cancers (Basel) 15: 4479.
9.
Patel SP, Kurzrock R (2015): PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14: 847-856.
10.
Pardoll DM (2012): The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
11.
Schreiber RD, Old LJ, Smyth MJ (2011): Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565-1570.
12.
Ghebeh H, Mohammed S, Al-Omair A, et al. (2006): The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198.
13.
Dong H, Strome SE, Matteson EL, et al. (2003): Co-stimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 111: 363-370.
14.
Seo SK, Seo HM, Jeong HY, et al. (2006): Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 102: 222-228.
15.
Sharma P, Shen Y, Wen S, et al. (2007): CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104: 3967-3972.
16.
Piersma SJ, Jordanova ES, van Poelgeest MI, et al. (2007): High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67: 354-361.
17.
Galon J, Costes A, Sanchez-Cabo F, et al. (2006): Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
18.
Zhang L, Conejo-Garcia JR, Katsaros D, et al. (2003): Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
19.
Cimino-Mathews A, Ye X, Meeker A, et al. (2013): Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol 44: 2055-2063.
20.
Cimino-Mathews A, Thompson E, Taube JM, et al. (2016): PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 47: 52-63.
21.
Szekely B, Bossuyt V, Li X, et al. (2018): Immunological differences between primary and metastatic breast cancer. Ann Oncol 29: 2232-2239.
22.
Yu P, Fu YX (2006): Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86: 231-245.
23.
Drake CG, Jaffee E, Pardoll DM (2006): Mechanisms of immune evasion by tumors. Adv Immunol 90: 51-81.
24.
Hammond ME, Hayes DF, Dowsett M, et al. (2010): American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795.
25.
Wolff AC, Hammond M, Allison KH, et al. (2018): Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36: 2105-2122.
26.
Nanda R, Chow LQ, Dees EC, et al. (2016): Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 34: 2460-2467.
27.
Salgado R, Denkert C, Demaria S, et al. (2015): International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26: 259-271.
28.
Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019): Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19: 307-325.
29.
Li X, Warren S, Pelekanou V, et al. (2019): Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. J Immunother Cancer 7: 88.
30.
Stanton SE, Disis ML (2016): Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4: 59.
31.
Schalper KA, Velcheti V, Carvajal D, et al. (2014): In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20: 2773-2782.
32.
Mao X, Zhou D, Lin K, et al. (2023): Single-cell and spatial transcriptome analyses revealed cell heterogeneity and immune environment alternations in metastatic axillary lymph nodes in breast cancer. Cancer Immunol Immunother 72: 679-695.
33.
Wu R, Oshi M, Asaoka M, et al. (2023): Intratumoral tumor infiltrating lymphocytes (TILs) are associated with cell proliferation and better survival but not always with chemotherapy response in breast cancer. Ann Surg 278: 587-597.
34.
Dong H, Zhu G, Tamada K, et al. (1999): B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365-1369.
35.
Taube J M, Anders R A, Young G D, et al. (2012): Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127r-137r.
36.
Boman C, Zerdes I, Mårtensson K, et al. (2021): Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev 99: 102257.
37.
Rozenblit M, Huang R, Danziger N, et al. (2020): Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer 8: e001558.
38.
Angelico G, Broggi G, Tinnirello G, et al. (2023): Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: A review of current evidence and prognostic implications from pathologist’s perspective. Cancers (Basel) 15: 4479.
39.
Ghebeh H, Barhoush E, Tulbah A, et al. (2008): FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 8: 57.
40.
Muenst S, Soysal S D, Gao F, et al. (2013): The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139: 667-676.
41.
Tsang JY, Au WL, Lo KY, et al. (2017): PD-L1 expression and tumor-infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat 162: 19-30.
42.
Schreiner B, Mitsdoerffer M, Kieseier B C, et al. (2004): Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 155: 172-182.
43.
Flies DB, Sandler BJ, Sznol M, et al. (2011): Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 84: 409-421.
44.
Sfanos KS, Bruno TC, Meeker AK, et al. (2009): Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 69: 1694-1703.
45.
Li X, Li M, Lian Z, et al. (2016): Prognostic role of programmed death ligand-1 expression in breast cancer: A systematic review and meta-analysis. Target Oncol 11: 753-761.
46.
Xie Q, Zhang P, Wang Y, et al. (2022): Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 12: 958720.
47.
Su H, Geng H, Cai L, et al. (2023): Immune-check blocking combination multiple cytokines shown curative potential in mice tumor model. Cancer Med 12: 13573-13585.
48.
Yan S, Wang W, Zhu B, et al. (2020): Construction of nomograms for predicting pathological complete response and tumor shrinkage size in breast cancer. Cancer Manag Res 12: 8313-8323.
